Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
about
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort studyPTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational studyDetection of Polyps After Resection of Colorectal CancerPrognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancerA genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.Current and future biomarkers in the treatment of colorectal cancer.Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer.Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function.Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer.Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
P2860
Q36028658-F1FFEE50-3927-4C50-A5DB-64DBD5ACDEA2Q36050773-F11D4049-729A-41FF-B208-0A995CEB7C96Q36279671-8A09B1D1-AB8F-40AE-A973-13B259B08493Q37098312-54B77023-C31A-46EB-8D6E-0E44E7789A18Q37735989-5E3E1DE3-CE6C-45B2-A22D-DC9949E0EBC5Q38787244-03C04114-749A-42B0-8270-AFE2800AC17EQ38847613-40AD3328-2EF3-4E52-BDA8-DC4EAB54639DQ40428222-9E0098BF-CCB5-493A-83AC-559F41B8F67AQ41608501-6A7B2A99-65D7-4C93-9211-7B1827CB39C6Q46099008-7A465D30-273B-48B0-A15D-DF04B641F9F5Q49569642-2D3442BC-A635-4DCF-A7EB-73C6464A409FQ51000263-D3A8642B-BC4D-4BC3-A2A0-C8DA2311866EQ53376512-190E861D-6197-4525-8008-CD3C803FFF19Q55154019-2B246149-F5B5-4ADF-BC70-2D27DD5B45F6
P2860
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@ast
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@en
type
label
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@ast
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@en
prefLabel
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@ast
Distinct gene expression profi ...... ytotoxic and targeted therapy.
@en
P2093
P2860
P356
P1476
Distinct gene expression profi ...... cytotoxic and targeted therapy
@en
P2093
C L Stephens
J H Hsiang
M K H Maus
S H Astrow
T Wakatsuki
P2860
P2888
P304
P356
10.1038/TPJ.2014.73
P577
2014-12-23T00:00:00Z